These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 33034194)

  • 1. Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1).
    Kanouni T; Severin C; Cho RW; Yuen NY; Xu J; Shi L; Lai C; Del Rosario JR; Stansfield RK; Lawton LN; Hosfield D; O'Connell S; Kreilein MM; Tavares-Greco P; Nie Z; Kaldor SW; Veal JM; Stafford JA; Chen YK
    J Med Chem; 2020 Dec; 63(23):14522-14529. PubMed ID: 33034194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1.
    Dai XJ; Liu Y; Xue LP; Xiong XP; Zhou Y; Zheng YC; Liu HM
    J Med Chem; 2021 Mar; 64(5):2466-2488. PubMed ID: 33619958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation.
    Schulz-Fincke J; Hau M; Barth J; Robaa D; Willmann D; Kürner A; Haas J; Greve G; Haydn T; Fulda S; Lübbert M; Lüdeke S; Berg T; Sippl W; Schüle R; Jung M
    Eur J Med Chem; 2018 Jan; 144():52-67. PubMed ID: 29247860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New tranylcypromine derivatives containing sulfonamide motif as potent LSD1 inhibitors to target acute myeloid leukemia: Design, synthesis and biological evaluation.
    Liang L; Wang H; Du Y; Luo B; Meng N; Cen M; Huang P; Ganesan A; Wen S
    Bioorg Chem; 2020 Jun; 99():103808. PubMed ID: 32334189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tranylcypromine Based Lysine-Specific Demethylase 1 Inhibitor: Summary and Perspective.
    Dai XJ; Liu Y; Xiong XP; Xue LP; Zheng YC; Liu HM
    J Med Chem; 2020 Dec; 63(23):14197-14215. PubMed ID: 32931269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tying up tranylcypromine: Novel selective histone lysine specific demethylase 1 (LSD1) inhibitors.
    Ji YY; Lin SD; Wang YJ; Su MB; Zhang W; Gunosewoyo H; Yang F; Li J; Tang J; Zhou YB; Yu LF
    Eur J Med Chem; 2017 Dec; 141():101-112. PubMed ID: 29031059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tranylcypromine-Based LSD1 Inhibitors: Structure-Activity Relationships, Antiproliferative Effects in Leukemia, and Gene Target Modulation.
    Fioravanti R; Romanelli A; Mautone N; Di Bello E; Rovere A; Corinti D; Zwergel C; Valente S; Rotili D; Botrugno OA; Dessanti P; Vultaggio S; Vianello P; Cappa A; Binda C; Mattevi A; Minucci S; Mercurio C; Varasi M; Mai A
    ChemMedChem; 2020 Apr; 15(7):643-658. PubMed ID: 32003940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and Structural Evaluation of N-Alkylated trans-2-Phenylcyclopropylamine-Based LSD1 Inhibitors.
    Niwa H; Sato S; Handa N; Sengoku T; Umehara T; Yokoyama S
    ChemMedChem; 2020 May; 15(9):787-793. PubMed ID: 32166890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based design and discovery of potent and selective lysine-specific demethylase 1 (LSD1) inhibitors.
    Nie Z; Shi L; Lai C; Severin C; Xu J; Del Rosario JR; Stansfield RK; Cho RW; Kanouni T; Veal JM; Stafford JA; Chen YK
    Bioorg Med Chem Lett; 2019 Jan; 29(1):103-106. PubMed ID: 30409536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying the novel inhibitors of lysine-specific demethylase 1 (LSD1) combining pharmacophore-based and structure-based virtual screening.
    Sun XD; Zheng YC; Ma CY; Yang J; Gao QB; Yan Y; Wang ZZ; Li W; Zhao W; Liu HM; Ding L
    J Biomol Struct Dyn; 2019 Oct; 37(16):4200-4214. PubMed ID: 30366512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of selective and reversible LSD1 inhibitors with anti-metastasis activity by high-throughput docking.
    Li L; Li R; Wang Y
    Bioorg Med Chem Lett; 2019 Feb; 29(4):544-548. PubMed ID: 30611617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of new tranylcypromine derivatives as highly potent LSD1 inhibitors.
    Huang MJ; Guo JW; Fu YD; You YZ; Xu WY; Song TY; Li R; Chen ZT; Huang LH; Liu HM
    Bioorg Med Chem Lett; 2021 Jun; 41():127993. PubMed ID: 33775841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural basis for the inhibition of the LSD1 histone demethylase by the antidepressant trans-2-phenylcyclopropylamine.
    Yang M; Culhane JC; Szewczuk LM; Jalili P; Ball HL; Machius M; Cole PA; Yu H
    Biochemistry; 2007 Jul; 46(27):8058-65. PubMed ID: 17569509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis of Carboxamide-Containing Tranylcypromine Analogues as LSD1 (KDM1A) Inhibitors Targeting Acute Myeloid Leukemia.
    Teresa Borrello M; Benelkebir H; Lee A; Hin Tam C; Shafat M; Rushworth SA; Bowles KM; Douglas L; Duriez PJ; Bailey S; Crabb SJ; Packham G; Ganesan A
    ChemMedChem; 2021 Apr; 16(8):1316-1324. PubMed ID: 33533576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
    Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
    J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluorinated tranylcypromine analogues as inhibitors of lysine-specific demethylase 1 (LSD1, KDM1A).
    Borrello MT; Schinor B; Bartels K; Benelkebir H; Pereira S; Al-Jamal WT; Douglas L; Duriez PJ; Packham G; Haufe G; Ganesan A
    Bioorg Med Chem Lett; 2017 May; 27(10):2099-2101. PubMed ID: 28390942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of the triazole-fused pyrimidine derivatives as highly potent and reversible inhibitors of histone lysine specific demethylase 1 (LSD1/KDM1A).
    Li Z; Ding L; Li Z; Wang Z; Suo F; Shen D; Zhao T; Sun X; Wang J; Liu Y; Ma L; Zhao B; Geng P; Yu B; Zheng Y; Liu H
    Acta Pharm Sin B; 2019 Jul; 9(4):794-808. PubMed ID: 31384539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD86 expression as a surrogate cellular biomarker for pharmacological inhibition of the histone demethylase lysine-specific demethylase 1.
    Lynch JT; Cockerill MJ; Hitchin JR; Wiseman DH; Somervaille TC
    Anal Biochem; 2013 Nov; 442(1):104-6. PubMed ID: 23911524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of JL1037 as a novel, specific, reversible lysine-specific demethylase 1 inhibitor that induce apoptosis and autophagy of AML cells.
    Liu S; Lu W; Li S; Li S; Liu J; Xing Y; Zhang S; Zhou JZ; Xing H; Xu Y; Rao Q; Deng C; Wang M; Wang J
    Oncotarget; 2017 May; 8(19):31901-31914. PubMed ID: 28404874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment.
    Zheng YC; Yu B; Jiang GZ; Feng XJ; He PX; Chu XY; Zhao W; Liu HM
    Curr Top Med Chem; 2016; 16(19):2179-88. PubMed ID: 26881714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.